UBRELVY Trademark

Trademark Overview


On Wednesday, November 7, 2018, a trademark application was filed for UBRELVY with the United States Patent and Trademark Office. The USPTO has given the UBRELVY trademark a serial number of 88185227. The federal status of this trademark filing is REGISTERED as of Tuesday, June 9, 2020. This trademark is owned by Allergan Pharmaceuticals International Limited. The UBRELVY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable ...
ubrelvy

General Information


Serial Number88185227
Word MarkUBRELVY
Filing DateWednesday, November 7, 2018
Status700 - REGISTERED
Status DateTuesday, June 9, 2020
Registration Number6075800
Registration DateTuesday, June 9, 2020
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 5, 2019

Trademark Statements


Description of MarkThe mark consists of the word "UBRELVY" below two wavy lines, both of which generally begin above the "E" in "UBRELVY" and extend in opposite directions.
Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, November 24, 2018
Primary Code005
First Use Anywhere DateWednesday, January 22, 2020
First Use In Commerce DateWednesday, January 22, 2020

Trademark Owner History


Party NameAllergan Pharmaceuticals International Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCoolock, Dublin 17 D17E400
IE

Party NameAllergan Pharmaceuticals International Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCoolock, Dublin 17 D17E400
IE

Party NameAllergan Pharmaceuticals International Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCoolock, Dublin 17 D17E400
IE

Trademark Events


Event DateEvent Description
Saturday, November 24, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 10, 2018NEW APPLICATION ENTERED
Tuesday, November 27, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, January 24, 2019ASSIGNED TO EXAMINER
Friday, January 25, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 13, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2019PUBLISHED FOR OPPOSITION
Tuesday, April 30, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, October 28, 2019SOU EXTENSION 1 GRANTED
Monday, October 28, 2019SOU TEAS EXTENSION RECEIVED
Monday, October 28, 2019SOU EXTENSION 1 FILED
Monday, April 6, 2020USE AMENDMENT FILED
Saturday, May 2, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 9, 2020REGISTERED-PRINCIPAL REGISTER
Monday, June 9, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, October 30, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 6, 2020TEAS STATEMENT OF USE RECEIVED
Monday, April 20, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 20, 2020STATEMENT OF USE PROCESSING COMPLETE
Friday, May 1, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED